Skip to main content

Author: The Wistar Institute

Dr. Cori Bargmann: A Q&A with the Winner of the 2023 Helen Dean King Award

Wistar researchers, staff and guests gathered to present the 2023 Helen Dean King Award to Dr. Cori Bargmann, Torsten N. Wiesel Professor and head of the Lulu and Anthony Wang Laboratory of Neural Circuits and Behavior at The Rockefeller University. Dr. Bargmann was recognized for her work exploring the genetic and neural circuit mechanisms of behavior in pursuit of understanding how genes influence decisions.

The award, established in 2016 to honor women who have achieved distinction in biomedical research, is named after Dr. Helen Dean King, a well-respected geneticist and member of Wistar’s research staff from 1908 to 1950.

We sat down with Dr. Bargmann to learn more about the nature of her research and its applications.

The human brain has 86 billion neurons, but the worms you study have 302 neurons in their whole body. Just how similar are their neural functions to ours?

There’s no question that worms have much simpler capabilities and information processing than humans. Worms are never going to speak French or play the piano. There’s a limit to what their central nervous systems can do — and a limit to how far you can apply and understand many important processes in human psychology, cognition, neurology, and so on.

One of the big surprises, even to those of us who work in invertebrate biology, was the discovery that genes encoded in the genome and active in the nervous system are actually highly conserved among different species. So, 75% of the genes that are present in a human are present in other animals, including invertebrates. And that includes many of the genes that are implicated in human neurological, developmental, or psychiatric disorders.

I remember going to the first talk that uncovered some of the genetic risk factors for bipolar disorder. Ed Scolnick used large-scale human studies to identify two genes implicated in these diseases, and it turned out that they were the exact same two genes that my lab was studying in C. elegans at the time. That really confirmed that the machinery used to build complex brains is really the same as the machinery that’s being used to build simple brains. You can study it in a complex system or a simple system, but underneath it all, it’s the same machinery. Genes are like a vocabulary of biology, and our genes speak the same fundamental language for all animals.

Your work looks at how neurons can form circuits in response to genes and environmental cues. How rigid or flexible are these connections?

We certainly know that many animals — worms, mice, even people — can sometimes have an experience that they then remember for their entire life. These long-lasting changes in the brain stabilize and become very robust over time. But there are other forms of flexibility in the brain that are much more dynamic and transient; these functional connections can form and dissolve as needed. That kind of dynamism is also present in worms.

Learning and memory excite many researchers, but we’ve been less focused on cognition per se than studying how neurons can form reversible functional networks. When an animal is in a good environment, it will generate one set of behaviors, but when it moves to a stressful environment, it will just flip and generate a completely different set of behaviors with the same nervous system. In complex organisms like mice and people, even these kinds of basic nervous system reactions are incredibly elaborate because of the sheer number of neurons. But in the worm, you can really see how this exceptionally small system can give rise to completely different behaviors. There aren’t nearly enough neurons to accommodate a “one neuron, one function” design. So worms rewire their machinery somehow, actively and dynamically — and that’s something in which my lab is very interested.

I’m only looking at 302 neurons, so I can realize a more detailed sense of what’s causing a response than I could if I were to look at your brain. These worms are working with the same molecular machinery as you and me — and applying it to fewer neurons. You’ve heard of oxytocin, serotonin, and dopamine; all these molecules are present and fulfill similar roles in these tiny organisms as they do in our massive brains.

The worms’ simplicity allows us to better understand ourselves because the biology is the same all the way down, even to the simplest organisms. Brains are like computers. Now think about the history of computers. The circuitry in your laptop or even your cell phone is obviously much more advanced than the vacuum tubes from the 1950s — but a transistor is a transistor. In the same way, a neuron is a neuron.

How do you go from a small-scale understanding of neurobiology to understanding complex disorders and pathologies?

Because worms have very simple systems — we can uncover useful information about how neuronal systems work. And that can inform how other researchers might approach something like an anxiety disorder or autism.

We humans have complex interpersonal experiences and inner lives. While I know that we can sometimes look at something like a mother mouse defending her young and anthropomorphize because we recognize similar behaviors in ourselves, my research has taught me to instead zoo-morphize humans. Remember during the height of the pandemic, when we were locking down, when a lot of us were feeling on-edge and irritable? Well, it turns out that if you stick a mouse in isolation for two weeks, its brain produces a lot of certain neuropeptides called tachykinins, which cause it to be more aggressive and fearful. All this is to say that biology is biology. Studying neurobiology at the minute level can help us humans understand when that biology is working with us as well as when it’s working against us.

Congratulations on receiving the Dr. Helen Dean King award, whose story is quite an inspirational one. Was there any scientist whose work inspired you to become the researcher you are today?

My own love of the problems that I study in behavior was inspired by the work of classical neurobiologists in the 1930s. Studies like those of Konrad Lorenz, who studied parental behaviors and the bonding of mother and offspring — what’s called imprinting.

Then there’s Karl von Frisch, who studied the honeybee waggle dance. And, of course, Nikolaas Tinbergen, who studied innate aggressive behaviors. There’s a famous story about Tinbergen having a fish in a fishbowl on his windowsill. A red mail truck comes by, and the fish goes into a highly aggressive display because the fish is a red fish — he thinks the truck is another male. What those scientists in the 1930s were saying is, “Look, there are parts of behavior that are shared by every individual in a species and the behaviors are innate.” But they knew nothing of genes, or DNA, or how that might work.

Today, scientists like me look at these shared behaviors and say, “Hey, there must be something genetic underlying these patterns; each behavior must be encoded in a genetic template.” And then we ask questions: What is that template? What genes are involved, and how do they work? Those initial discoveries inspired me to think about these questions and how to answer them. That fish in the bowl, almost 100 years ago, was displaying exactly the same kind of behavior that my lab and many others are studying. Except now, we know which neuropeptides the red mail truck triggers in the fish.

Last question: favorite neurotransmitter?

Ah, that’s not fair, they’re all great! I’m not prepared to choose a favorite. That said, serotonin is very interesting in the way that it can achieve paradoxical effects. I’d say at any given time, I’m most attached to the neurotransmitter I don’t understand yet.

2023 Champion Run for Research Takes to the Streets to Support Wistar Trainees

A group of more than 35 Wistar trainees, researchers, staff, and family members donned their sneakers, stretched their hamstrings, and took to the sidewalks of University City on November 13 to participate in the annual Wistar Run for Research. Wistar’s Education and Training team was on hand with donuts, coffee, and water to keep everyone adequately fueled for the trek. 

Beginning at The Wistar Institute on 36th and Spruce St, participants in the two-mile fun run/walk snaked their way down Spruce St., across the South St. Bridge, and along the banks of the Schuylkill toward the finish line at the Philadelphia Art Museum.

Culminating at the foot of the iconic Rocky statue adjacent to the museum, participants gathered around the symbol of Philly’s grit and raised their arms in triumph. Several finishers even performed the traditional run up the art museum steps, emulating Sylvester Stallone’s famous scene from the 1976 movie. 

“We’re really excited by the turnout and the amount we were able to raise,” said Brennah Britten, co-president of the Wistar Trainee Association and a participant in the walk. “This is a great way for us to showcase the work that we do and help raise funds for the association at the same time.”

The event raised more than $5,000, eclipsing the trainee association’s goal by $1,000 and setting a new fundraising milestone for the annual event. Funds raised go toward training, education, and the development of our next generation of biomedical researchers.

Thank you to all that participated!  

How Does our Immune System Respond to Vaccines? 

A Q&A with Wistar’s Dr. Amelia Escolano

What got you interested in immunology?

My interest in immunology started in college. I took several immunology courses, and I was particularly attracted by antibody biology. One of these courses was Immunotechnology, and I remember being fascinated by the immense potential of antibodies for immunotherapy development. This interest further developed during my Ph.D. studies, which focused on macrophages, a type of immune cell. I investigated the role of calcineurin, a phosphatase enzyme, in macrophage polarization. In other words, I studied how calcineurin determined the specific pro- or anti-immune functions of macrophages and how this could impact the progression and outcomes of inflammatory processes.

The immune system is immensely complex. It is a very sophisticated and orchestrated network of immune mediators that interact and influence each other to provide protection against pathogenic threats. We have so much to learn about the many different immune cells and the cellular and molecular mechanisms involved in immune responses; the complexity and ingenious mechanisms of the immune system make it a very exciting area of study.

In addition to my interest in shedding light on some aspects of the immune response, the fact that the implications of immune system research are so clearly beneficial to human health makes this area of research very attractive to me and my team.

Now, in your lab, you investigate the mechanisms governing the immune responses to vaccines. Very broadly, can you tell us about that work?

Our research revolves around vaccine design; that’s the goal that informs our approach. We are interested in understanding how B cells and T cells respond to vaccination so that we can leverage this information to design better vaccines. In particular, we study the process of antibody affinity maturation.

Affinity maturation is the process by which antibodies are produced and refined to target a specific antigen, a component of a pathogen that activates the immune system. Antibody affinity maturation takes place in the germinal centers, which are anatomical sites where B cells work with a certain kind of T cell called T follicular helper (Tfh) cells to iteratively refine and test their B cell receptors — otherwise known as antibodies. This process allows the immune system to improve its antibody responses.

With this process in mind, we aim to understand how a vaccine should be designed so that the elicited antibody response can efficiently prevent infectious diseases for long periods of time.
In my lab, we study the immune response to sequential immunization in the context of HIV-1. Sequential immunization is a novel form of vaccination that requires multiple boost immunizations with different but related viral proteins. In the case of HIV-1, sequential immunization involves multiple boost immunizations with different versions of the envelope protein of HIV-1.

Sequential immunization takes advantage of the antibody affinity maturation process with the ultimate goal of getting the immune system to produce high-quality antibodies that can fight complex, highly variable viruses like HIV.

We analyze how B cell populations and their antibodies evolve in response to sequential immunization, and we’re testing strategies to make that antibody affinity maturation more efficient by focusing on both B cells and T follicular helper cells.

Why is sequential immunization necessary against HIV-1?

To vaccinate effectively against HIV, we need B cells to produce what we call a broadly neutralizing antibody, or bNAb. bNAbs are rare antibodies that can neutralize multiple different variants of HIV-1, and we expect a vaccine that elicits bNabs to protect effectively against HIV-1.

Our previous work showed that repeated immunization with the same HIV-1 envelope protein was not capable of inducing bNAbs. Instead, sequential immunization efficiently induced antibodies that potently neutralized a large number of different HIV-1 variants.

In a sequential immunization protocol, we start with an engineered HIV-1 envelope immunogen, which is a term that we use to describe an antigen we’re testing as a vaccine candidate. The role of this first immunogen is to activate a rare subset of B cells that have receptors with the capacity to be refined into bNAbs. These B cells respond to this first immunogen and increase their affinity for it.

That increase in affinity for the first immunogen is associated with an increase in affinity for a slightly more complex HIV-1 envelope immunogen, which is then used for a second immunization. Sequential immunization repeats this process multiple times as a way of gradually increasing the affinity of B cells for the unmodified wild-type, or naturally occurring, HIV-1 envelope protein. We nudge B cells along to make sure that they mature in a way where they get progressively better at reacting to different HIV-1 strains.

How are you able to tell that your sequential vaccination protocol has produced a broadly neutralizing antibody? What do you look for?

We test our sequential immunization protocols by looking at blood after vaccination and running what’s called a serum neutralization assay. This assay can determine whether the mix of antibodies in the blood, elicited upon vaccination, can neutralize different HIV-1 strains. The number of different HIV-1 strains that the serum antibodies can neutralize determines the breadth of these antibodies. This assay also informs us of the potency of the antibodies to neutralize each HIV-1 strain.

In addition to these neutralization assays, we analyze B cells from lymph node tissue to see which antibodies they’re expressing. We are then able to evaluate individual antibodies for their capacity to neutralize HIV-1. These evaluations help us refine our vaccine candidates and sequential immunization protocols by showing us what’s working and what isn’t.

For how long has this immunology work been your focus?

I’ve been working on this approach for HIV vaccine development since I started my postdoctoral studies in the Nussenzweig laboratory at The Rockefeller University in 2014. Now, at The Wistar Institute, where I established my independent lab two years ago in September of 2021, my lab is expanding this research.

I came to The Wistar Institute with a vision of what I wanted my science to be, and Wistar has helped make that vision a reality. Here, I have found great colleagues, I have established fantastic collaborations both at Wistar and UPenn and I have seen my program grow exponentially. I’ve also found great opportunities to explore other research areas that have strengthened my program’s approach.

I find it hard to believe that two years have gone by already; the time has been both positive and productive. The welcome and support I’ve had at Wistar make me feel like a real part of a community. I can tell that all my Wistar colleagues — across the labs, across the departments — have an investment in seeing our science succeed.

From Lab to Laptop: The Interdisciplinary World of Computational Biology 

Wistar’s Dr. Avi Srivastava seamlessly integrates elements of computer science and traditional biology into his new computational biology research lab. By combining wet and dry lab approaches — experimental biology and computational data — he can be innovative in research derived from both worlds. Here’s how he does it.

What is computational biology?

Computational biology is different for different people. For me, the fine line between bioinformatics and computational biology is a live question, but we can think about computational methods intersecting with biology in two basic ways.

The first element is existing methods. These are open-source tools that exist on the internet as downloadable, which can then be applied to data and generate something useful. When scientists talk about “mining” datasets, they’re using tools like this on a particular dataset. This large area of research takes a good deal of resources, and many scientists interact with computational elements of research on this level.

Let’s define open source. Open source is freely accessible. An example might be an algorithm that can analyze RNA data in bulk to look for a particular pattern associated with something, maybe a disease biomarker. Scientists can simply download that algorithm, execute it on the dataset they’re interested in, and interpret the results. So, using these existing methods to answer questions about biological data is the first component of computational biology.

The second component would be the actual development of those tools. Someone has to develop them, right? And I relish in developing new methods; that’s who I am. Every software method in the field of biology needs to be informed biologically, through experimentation. That’s how you make these tools better. It’s not just sitting in your room on your laptop coding for hours — it’s getting in the lab to understand how the biology behind the code works.

Once you understand the tools’ foundations and limitations, you can modify lab experiments and refine methods. This process complements itself through experimenting, collaborating, and refining. Computational biology loops from lab to code to lab — a virtuous circle that continues to improve, because the field moves so fast.

How long has computational biology existed and when did it emerge as a field?

I think that computational biology grew out of computer science. Now, computer science has been around for ages; we can go all the way back to Turing machines, or even further. But I think that the Human Genome Project in the 1990s really opened a lot of scientists’ eyes to the power of combining computer science with biological research.

The Human Genome Project developed enormous data sets, and back then, the sequencing technologies weren’t advanced enough to sequence long segments of DNA. So, scientists began to ask themselves how they could chop up the human genome into segments of DNA for sequencing and then reassemble the human genome from those chunks. To do that, they turned to computer methods.

Think of it like file compression, when you email a picture and it loses some image quality: that’s what scientists did to the human genome, and I believe that’s the time computational biology came into its own. Since then, the field has matured and tech has improved, and our ability to “see” more of the genome has improved too, because we can process more data.

Software and code can change very quickly. How do you stay up-to-date on all the new developments in the field?

Staying current in the field is one of the million-dollar questions in computational biology, and I don’t know that anyone has cracked it. Because with software and open-source code, things do move fast, and scientists want to use the best, latest methods to answer their research questions.

In my experience, you have to orient your lab around reading papers efficiently. Rather than spending an hour on every paper and discussing it in-depth, I like the setup of my previous boss where I have my lab discuss four papers in an hour when reviewing the literature. In general, we keep 15 minutes a paper to get a broader sense of the method, what’s new, and how we can learn from it — and then we selectively discuss relevant papers in-depth. It’s not a perfect solution, but it helps you get a broader perspective of the way the field is growing.

The pace of the science makes computational biology exciting, in part because the changing tech is a challenge in its own right, and scientists like me love a good challenge.

What do you see as the Srivastava Lab’s role in such a dynamic research landscape?

Computational biology methods should be adjustable and easy to use, but I think the field needs better tools and better support for those tools. When I say “support,” I mean that if I download software and it doesn’t work except in one specific circumstance, then that tool has very limited use for the broad scientific community. It’s a big problem when some papers can’t even be replicated using the same methods because of a lack of support from the developers. With well-supported tools, researchers can utilize the method effectively, which is necessary for reproducing and verifying results.

Yes, we need to make sure programs and tools work properly, but providing support when building them allows diverse applications by allowing scientists to adapt these tools to their own research questions. When programs are tweaked and iterated upon, scientists can get creative and research flourishes — but that can only happen if those tools are built in a way that lets scientists tweak them easily.

I will support those kinds of innovative alterations in the way I go about developing tools, but also by keeping the user in mind and providing tutorials, instructional PDFs, videos, etc. That takes time, but if you’re invested in your methods, providing that support can make them even more impactful.

What excites you about the field and your work in it?

We talked about this computational biology “loop” — code feeds into the wet lab, which feeds into the code, and so on. I’m very excited to be at Wistar working on both sides of that loop; many scientists focus on one or the other, but my lab is focused on bringing both the lab and the code to the fore simultaneously.

That’s an exciting space to be in because we have so much room for interdisciplinary discovery and collaboration. I can work with computer scientists who want to learn more about biology, and I can work with biologists who want to learn more about coding. My lab is interested in the epigenome — how the genome is modified — because it’s important for so many different processes and disease states across cell types. By focusing on the computational and the biological, I think we have a tremendous opportunity to build tools that will give us a more detailed understanding of the epigenome’s complexities.

Wistar Scientists Engineer New NK cell Engaging Immunotherapy Approaches to Target and potentially Treat recalcitrant Ovarian Cancer

PHILADELPHIA—(Nov. 1, 2023)— The Wistar Institute’s David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center (VIC) and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research, and collaborators, have engineered novel monoclonal antibodies that engage Natural Killer cells through a unique surface receptor that activates the immune system to fight against cancer.

In their publication titled, “Siglec-7 glyco-immune binding MAbs or NK cell engager biologics induce potent anti-tumor immunity against ovarian cancers,” published in Science Advances, the team demonstrates the preclinical feasibility of utilizing these new cancer immunotherapeutic approaches against diverse ovarian cancer types, including treatment-resistant and refractory ovarian cancers — alone or in combination with checkpoint inhibitor treatment.

The research started as a collaboration between Wistar’s Drs. Weiner and Mohamed Abdel-Mohsen, who were exploring the development of new glyco-signaling biologic tools that may be important in the fight against cancer.

Ovarian cancer (OC) is frequently diagnosed late in the disease process, and OC resistance to currently available treatments make it especially problematic; according to the NIH, the chances of someone diagnosed with OC and surviving for five years is around fifty-fifty. Ovarian cancer demonstrates a low response rate to standard-of-care treatments like chemotherapies, PARP inhibitors and the widely used checkpoint inhibitor, PD-1.

In the small proportion of ovarian cancer patients that do respond to these treatments, resistance becomes problematic over time — resulting in tumor escape and cancer progression. Genetic mutations, such as the well-known BRCA gene mutations, predispose women to a high risk of progressive OC. The CDC expects more than thirteen thousand women to die of ovarian cancer this year in the U.S. alone.

To combat ovarian cancer treatment resistance, the team hypothesized that they might be able to engage not only the traditional T cell immune arm of the immune system which PD-1 and known checkpoint inhibitors (CPI) activate, but also implement a strategy to activate Natural killer cells (NK cells), a subset of important anti-tumor immune cells, through a conserved glyco-immune marker found on the surface of most NK cells called Siglec-7 (Sialic acid-binding immunoglobulin-type lectin). NK cells have been recently described to express Siglec-7, so the team tested two new strategies to engage and activate NK cells against ovarian cancer through Siglec-7.

The first approach used human monoclonal antibodies (mAb) discovered and developed at Wistar and novel assays to visualize and demonstrate that certain anti-Siglec-7 mAbs could activate human NK cells — which, in the presence of the antibodies, responded against multiple human OC cell lines. These now-activated NK cells would kill OC but not non-cancer cells with the Siglec-7 mAb treatment.

The researchers demonstrated that multiple OC carrying mutations, including BRCA1 and BRCA2, could be targeted by Siglec-7 antibodies through activated NK cells. The group moved to study the treatment of OC in a humanized mouse model and observed that the Siglec-7 treatment could impact OC growth slowing the tumors and increasing the animals’ survival.

Having demonstrated the feasibility of utilizing a Siglec-7 mAb in OC models, the team thought there were additional ways to use the Siglec-7 mAb to further focus on OC disease. They hypothesized that directly fusing the Siglec-7 reactive binding site of the Siglec-7 mAb to a second mAb that uniquely binds late OC through a molecule named Follicle Stimulating Hormone receptor (FSHR), which they had previously developed, would create a targeted Siglec-7 bispecific antibody that could bind through two distinct targets creating a new class of NK cell engagers (NKCE).

The team sought to test whether this Siglec-7 NKCE approach would be effective through the direct linkage of potentially killer NK cells to a guided missile aimed specifically at OC, which would open up a new path to develop additional Siglec-7 based immunotherapeutic approaches. In both bench and humanized mouse challenge studies, the Siglec-7-NKCE was effective at targeting OC, activating NK cells in local proximity and efficiently killing multiple OC.

Both Siglec-7 technologies (mAbs and NKCEs) demonstrated an ability to recruit and activate the NK cell population, shrink tumors and prolong survival in the models studied. The observation of on-target specificity of the approaches suggests that cancer’s apparent Siglec vulnerability can be exploited therapeutically, perhaps with limited toxicity — a promising sign for the future of anti-cancer Siglec research, but the team cautions that more work in this regard is important.

In an additional set of preliminary studies, the team also found that this Siglec-7 approach could complement PD-1 checkpoint inhibitor (CPI) therapy. This is an important area of further study that could uncover more details of the mechanisms involved and possibly extend the utility of such CPI in OC and, potentially, other cancers. “These findings open the door to further exploration of how we can engineer Siglec-7 immunotherapies and perhaps other related molecules for ovarian cancer and perhaps a larger group of recalcitrant cancers,” stated Dr. David B. Weiner, adding, “Further studies may bring such approaches as described to represent new tools in our antitumor toolbelt.”

As always, more research is needed to refine these technologies further on the long journey from the lab bench to the clinic. But this paper offers a different avenue for attempting to exploit these unique interactions of immune surface molecules such as Siglec-7 and perhaps other Siglecs.

“We have observed not one but two methods that can target NK cells in an effort to control ovarian cancer in both Petri dishes and in vivo models,” said Dr. Devivasha Bordoloi, the first author on the paper. “This research shows a lot of promise, and I’m excited to move these studies to the next steps.”

Co-authors: Devivasha Bordoloi, Abhijeet J. Kulkarni, Opeyemi S. Adeniji, Pratik S. Bhojnagarwala, Shushu Zhao, Candice Ionescu, Alfredo Perales-Puchalt, Elizabeth M Parzych, Xizhou Zhu, Ali R. Ali, Joel Cassel, Rugang Zhang, Mohamed Abdel-Mohsen and David B. Weiner of The Wistar Institute; and M. Betina Pampena and Michael R. Betts of Perelman School of Medicine, University of Pennsylvania,

Work supported by: Department of Defense Ovarian Cancer Research Program award W81XWH-19-1-0189; the W.W. Smith Charitable Trust Professorship in Cancer Research; and the Wistar Science Accelerator Postdoctoral Fellowship.

Publication information: “Siglec-7 glyco-immune binding MAbs or NK cell engager biologics induce potent anti-tumor immunity against ovarian cancers,” from Science Advances.

###

The Wistar Institute, the first independent, nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a culture of biomedical collaboration and innovation. Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology. Wistar has been producing groundbreaking advances in world health for more than a century, consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology. wistar.org.

Jesper Pallesen, MBA, Ph.D.

Assistant Professor, Vaccine & Immunotherapy Center

Pallesen received his Ph.D. degree from Aarhus University. He received his postdoctoral training at Columbia University and The Scripps Research Institute. Here, he specialized in cryo-electron microscopy of bio-molecular protein complexes relating to infectious disease and immunobiology. In parallel to his postdoctoral training, he has extensive experience as a technical consultant in IP law and he received his M.B.A. from Rady School of Management with specialization in statistics, finance and management. His group studies infectious disease and cancer and develops vaccines and immunotherapeutics from a structural biology guided approach.

View Publications

The Pallesen Laboratory

215-898-3941

jpallesen@wistar.org

The Pallesen Laboratory

Staff

Graduate Students

Jianqiu Du, M.S.
Jiayan Cui
ZiJie (Jerry) Lin

The Pallesen Lab in the News

Selected Publications

  • DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2.

    Parzych EM, Du J, Ali AR, Schultheis K, Frase D, Smith TRF, Cui J, Chokkalingam N, Tursi NJ, Warner BM, Gary EN, Li Y, Choi J, Eisenhauer J, Maricic I, Kulkarni A, Chu J, Villafana G, Rosenthal K, Ren K, Francica JR, Wootton S, Tebas P, Kobasa D, Broderick K, Boyer JD, Esser MT, Pallesen J, Kulp DW, Patel A, Weiner DB. “DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2.” Nat. Commun. 2022 Oct 6;13(1):5886.

  • The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template.

    Andrabi R*, Pallesen J*, Allen JD, Song G, Zhang J, de Val N, Gegg G, Porter K, Su CY, Pauthner M, Newman A, Bouton-Verville H, Garces F, Wilson IA, Crispin M, Hahn BH, Haynes BF, Verkoczy L, Ward AB, Burton DR. “The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template.” Cell Rep. 2019 May 21;27(8):2426-2441.e6.

  • Immunogenicity and Structures of a Rationally Designed Prefusion MERS-CoV Spike Antigen.

    Pallesen J*, Wang N*, Corbett KS*, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong W, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS. “Immunogenicity and Structures of a Rationally Designed Prefusion MERS-CoV Spike Antigen.” Proc Natl Acad Sci USA. 2017 Aug 29;114(35):E7348-E7357.

  • Open and Closed Structures Reveal Allostery and Pliability in the HIV-1 Envelope Spike.

    Ozorowski G*, Pallesen J*, de Val N, Lyumkis D, Cottrell CA, Torres JL, Copps J, Stanfield RL, Cupo A, Pugach P, Moore JP, Wilson IA, Ward AB. “Open and Closed Structures Reveal Allostery and Pliability in the HIV-1 Envelope Spike.” Nature. 2017 Jul 20;547(7663):360-363.

  • Structures of Ebola Virus GP and sGP in Complex with Therapeutic Antibodies.

    Pallesen J*, Murin CD*, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE Jr, Saphire EO, Ward AB. “Structures of Ebola Virus GP and sGP in Complex with Therapeutic Antibodies.” Nat Microbiol. 2016;1 pii: 16128. Epub 2016 Aug 8.

View Additional Publications

Continue reading

Navigating a Science Career: Wistar Alumni Share Their Career Journey at Inaugural Fireside Chat

Three Wistar alumni returned to their research roots to participate in Wistar’s first Fireside Chat forum as part of the Institute’s Diversity in Science initiative. In front of a video projection of a crackling fire, the trio spoke with humor, thoughtfulness, and disarming honesty to Wistar trainees about their career paths and what they’ve learned since leaving their respective Wistar labs.

The alumni – M. Cecilia Caino, Ph.D., Associate Professor of Pharmacology at the University of Colorado; Kevin Alicea-Torres, Ph.D., Assistant Professor of Cell & Molecular Biology at the University of Puerto Rico at Humacao; and Ademi Santiago-Walker, Ph.D. Head of Prostate and CRC Oncology Translation Research at Janssen Pharmaceutical – have diverged on their own unique paths, but agreed that their experiences and their Wistar connections were instrumental in helping them find their footing in academia and the corporate sector. 

Dr. Santiago-Walker, who trained as a postdoc in Dr. Meenhard Herlen’s lab, attributed her smooth transition into the pharmaceutical industry to the skills she learned at Wistar. “I use a lot of the transferable skills I learned in my time here,” she explained. “[Wistar] is a well-oiled machine and there’s a lot of great collaboration, so I had the opportunity to work in a matrixed team similar to what you have in pharma, where you’re working with multiple people from different functions to accomplish your goal.” 

Dr. Alicea-Torres explained that he received his Ph.D. just as the pandemic hit, adding an unplanned layer of complexity to the next step of his career. Although his path wasn’t clearly mapped out, he landed a Mass Media Fellowship that eventually led to a job as a science writer at Telemundo, something that combined his interest in communication with his scientific background. “I used my relationships to establish a network and learn about other opportunities. Networking is crucial, both inside and outside of the science community.” 

Throughout the wide-ranging discussion, the panelists answered a host of questions posed by the audience of trainees, including how to deal with self-doubt, diversifying your skillset, and ways to acquire “soft skills.”

“We’re always working on ourselves,” said Dr. Alicia-Torres. “Be humble throughout the process and be open to the feedback and advice that you receive. People may be observing something that you don’t see, and that might be the very thing you need to address to get that opportunity.”

The event was a joint effort between The Wistar Institute Inclusion Diversity & Equity Council (W-IDE), the Hubert J.P. Schoemaker Education and Training Center, and The Wistar Institute Trainee Association. Long term, the team plans to organize similar events to help budding researchers broaden their skills and learn from real-life experiences. “This event has been an amazing collaboration between a lot of different departments,” said Dr. Jessie Villanueva. “I hope that it’s the beginning of a new partnership between all of us to bring in similar future events.”

The Fireside Chat concluded with a networking reception that featured industry professionals from several local organizations including Spark Therapeutics, American Association of Cancer Research, and the University of Pennsylvania.

Notes from the Field: Dr. Ian Tietjen in Africa, Part 5

Dr. Ian Tietjen is a Research Assistant Professor in Wistar’s Montaner Lab, where he investigates traditional African medicinal compounds’ potential for drug origination against viruses like HIV. Dr. Tietjen travels to Africa to work with traditional healers to better understand the function of these compounds.

If you haven’t started this series with part one, click here.

9 August 2023 — After the big community session and the experimental workshop, today was a lighter day with the group. We travelled to Domboshaba, which is a cultural heritage site for the Kalanga peoples that was excavated nearly 100 years ago. The healers pointed out numerous plants that are used for medicines. The place has long been a site for training healers and general spiritual contact with the ancestors. After lunch, we gave some final speeches, and both the Secwepemc delegation and Kalanga healers serenaded all of us with their traditional songs. The healers are being driven home to their local villages or as far as Francistown.

They’re excited to work with biomedical researchers in a way that shares the benefits of collaboration between scientific partners.

Entrance and walk to the historic village.
On the left is a grinding stone and a wall continually rebuilt by people looking to preserve the village and continually torn down by baboons looking for insects to eat. Today the people won. On the right is the Chief’s residence, on top of a large hill. 

10 August 2023 — Today our group of researchers and some healers took a cultural trip out to the Elephant Sands park, where there are very few people but lots of wildlife. There is a watering hole nearby, and the elephants come up very close to you while you are eating lunch. 

Apart from the occasional village, herds of cattle, and the random elephant, it’s pretty much this for four hours. You don’t want to drive this road at night because the wildlife is frequently much larger than you.
On the left are weaver bird nests. In the middle is our van stuck in the sand. We all pushed and got it out, and the elephants stayed away. On the right are grass harvesters (for thatch, brooms, and other necessities.) returning home for the night. 
On the left is a very big tree. If you look close you can see Rhona at the bottom. On the right is what’s left of a large cattle herd.

On the way back one of the healers seemed to be getting more comfortable with us, asking a lot of questions about how HIV works and health science advice more generally. Afterwards, he treated us all to cups of sour milk from a roadside stand that also had Mopani worms, which are large grubs that are dried and salted. I’ve seen reality shows where contestants have to eat these in order to stay in the competition, but it was nowhere as bad as the shows made it out to be. 

Dr. Richard’s homestead, chicken coop, and homemade breakfast!
Local delicacies: mopani worms (left) and sour milk (right)!

Dean Stoios Joins The Wistar Institute as Chief Financial Officer

PHILADELPHIA (October 17, 2023) – The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious diseases, announces the appointment of Dean Stoios as Chief Financial Officer.

“We are thrilled to welcome Dean to Wistar,” said Dario C. Altieri, M.D., Wistar President & CEO, director of the Ellen and Ronald Caplan Cancer Center, and the Robert and Penny Fox Distinguished Professor. “He brings to the role a proven track record in financial leadership that will advance our strategic goals of driving breakthroughs in biomedical science and technology; develop more creative collaborations; will enable us to continue to grow our endowment and enhance our financial infrastructure and enterprise capabilities.”

Stoios comes to Wistar with more than 25 years of experience in strategic planning, financial management, and driving successful growth in both private and academic sectors. Most recently, Stoios served as CFO of the Coriell Institute for Medical Research, where he was instrumental in conceptualizing and executing a comprehensive vision of sustainable organizational growth, expanded NIH funding, and strategic planning that have been pivotal for the organization’s success. Prior to his role at Coriell, Stoios served in various leadership roles at clinical research organizations such as ICON PLC and Syneos Health and progressed through several roles at Aetna.

“I am very excited to become part of The Wistar Institute; its commitment to innovate through collaboration and its commitment to excellence in biomedical research have made it one of the most respected biomedical research organizations in the world,” said Stoios. “Wistar’s world-class scientists are committed to early-stage groundbreaking discoveries. I am honored to be a part of the leadership team.”

###

The Wistar Institute, the first independent, nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a culture of biomedical collaboration and innovation. Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology. Wistar has been producing groundbreaking advances in world health for more than a century, consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology. wistar.org

Notes from the Field: Dr. Ian Tietjen in Africa, Part 4

Dr. Ian Tietjen is a Research Assistant Professor in Wistar’s Montaner Lab, where he investigates traditional African medicinal compounds’ potential for drug origination against viruses like HIV. Dr. Tietjen travels to Africa to work with traditional healers to better understand the function of these compounds.

If you haven’t started this series with part one, click here.

7 August 2023 — Today was the opening session of our biomedical research project—a major undertaking to better identify and understand natural medicinal compounds. We’re meeting with the community before starting work to inform them about our collaboration with the healers and answer questions.

We began by meeting in the kgotla, which is the traditional meeting house of the village. Because Tutume is the local capital of the district, several Kgosi and Dikgosi, or chiefs and sub-chiefs, from Tutume and the neighboring villages all come to meet. These days everyone wears suits, but at minimum jackets, long skirts and covered shoulders are required in the kgotla. This is a formal session where the community can meet and give formal approval to our proposed plan. Anybody can attend, and in this case, it was broadcast on Botswana TV (BTV) and streamed on Facebook.

We each took a turn speaking about where we come from, what we hope to achieve, and what we hope to avoid. We also had a local poet present one of his works, and a local dancing troupe performed to traditional music. In return, the Secwepemc delegation sang and presented the Tutume Kgosi and a delegate of the Ministry of Education a copy of their book Secwepemc People, Land, and Laws (written by Ignace and Ignace), a 10,000-year history of their peoples. The Secwepemc and local healers are already starting to hit it off and trying to learn from each other how traditional medicines work.

Dr. Khumoekae Richard introducing the work we hope to do in Tutume.
Traditional Kalanga dancers on the left, and traditional Secwepemc singers on the right.
A super friendly cat back at the hotel.

8 August 2023 — Today was the big experimental day, and we all assembled into experimental groups to conduct collaborative research for the workshop. We brought a large amount of lab equipment and reagents as well as plant samples that were blinded to us (meaning we didn’t know what the samples were). In the morning, we ran an antioxidant assay, an assay to measure inhibition of alpha-glucosidase, and an assay to measure anti-trypsin activity. The antioxidant assay reagents spoiled, so we ran an alpha-glucosidase assay with both pure enzyme and pea sprouts, which have high levels of this enzyme.

Basically, alpha-glucosidase is an enzyme that catalyzes complex sugars and starches into simple sugars, which our body needs for energy. However, if there is too much sugar in the body, this can lead to diabetes. Alpha-glucosidase inhibitors from medicinal plants might be leads for future anti-diabetes therapies. We all worked together to run the assays on the blinded compounds.

Interestingly, we found that several medicinal plant extracts have alpha-glucosidase activity on their own, in the absence of pea shoots. Compared to the workshop group using the pure enzyme, we had the opposite results. So, one group found potential leads for anti-diabetes therapies, and we found leads for potentially treating low blood sugar.

The healers’ scientific judgment is sharp. We discussed how sample age and solvents could affect outcomes, and other healers commented on additional controls that could be added. One mentioned that just because this assay didn’t show activity for a certain plant doesn’t mean the plant is invalid — only that it didn’t work in this experiment. There was a lot of discussion among all us over lunch about other ways to target diabetes beyond alpha-glucosidase.

On the left, Richard, healers, and other community members test plant extracts for alpha-glucosidase activity. On the right, Kerstin and others test for anti-trypsin activity.
We have data!
All the workshop participants

After we conducted experiments, three participants gave result summaries and interpreted them. And their interpretations and results criticisms were spot-on. We then had a long discussion about the next steps of what we could do together. The healers were enthusiastic about future directions after the workshop, and they hope to continue collaborating with us to investigate other samples; there’s more work to be done, and everyone is excited to work together on it.

More scenes from Tutume:

Healer s talking shop